Look no further than GlaxoSmithKline shedding its consumer ... and deliver far higher returns for shareholders, research finds. Building the new vision starts with defining a credible and meaningf ...
Shares of GSK Plc. were gaining around 6 percent on the London Stock Exchange, as well as in the pre-market activity on the NYSE, ...
European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, Labour and ...
GSK’s Shingrix new prefilled syringe presentation accepted for review by European Medicines Agency
If approved, the new presentation will offer a convenient administration option to healthcare professionals Globally, up to 1 in 3 adults will develop shingles in their lifetime 1,2,3,4 Over 25 ...
GSK’s Shingrix new prefilled syringe presentation accepted for review by European Medicines Agency
5 This European regulatory review follows the file acceptance by the US FDA on 8 January 2025 for the new prefilled syringe presentation, continuing GSK’s commitment to providing solutions to ...
The University of Oxford and GSK are to work on a vaccine to target cells in the pre-cancerous stage (PA) Pharmaceutical giant GSK and the University of Oxford are creating a new cancer vaccine to ...
GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline.
when the partners teamed up to launch a new molecular and computational medicine institute. That collaboration formed on the back of a five-year, $40 million investment from GSK and focuses on ...
If approved by the EMA, this new option could streamline the vaccination process in clinical settings across Europe. GSK is a global biopharma company focused on uniting science, technology ...
Get Our Latest Stock Report on GSK GSK Stock Up 0.8 % GSK opened at $35.35 on Friday. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.92. The firm’s 50 day simple moving average is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results